glp-1 weight loss drug news today 2025 Alarming rise in overdoses The Trump administration is preparing
Description
Amy Schroeder Principal Research Scientist | July 9, 2025 Current Landscape Overview Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are an emerging drug class that are mostly indicated to improve glycemic control in patients with type 2 diabetes mellitus (T2D) and reduce body weight
, IL-6 and high-sensitivity CRP, 6)
This initially seemed problematic for a weight loss medication
95% CI 0.160.33) compared with the non-GLP-1 RAs group
While these medications can be beneficial for some, they can also come with unpleasant side effects like nausea, constipation and fatigue
